Drug Type Small molecule drug |
Synonyms GSK 239512, GSK-239512A, GSK239512 |
Target |
Mechanism H3 receptor antagonists(Histamine H3 receptor antagonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Molecular FormulaC23H27N3O2 |
InChIKeyYFRBKEVUUCQYOW-UHFFFAOYSA-N |
CAS Registry720691-69-0 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Multiple Sclerosis, Relapsing-Remitting | Phase 2 | BG | 01 Feb 2013 | |
Multiple Sclerosis, Relapsing-Remitting | Phase 2 | CA | 01 Feb 2013 | |
Multiple Sclerosis, Relapsing-Remitting | Phase 2 | CZ | 01 Feb 2013 | |
Multiple Sclerosis, Relapsing-Remitting | Phase 2 | DE | 01 Feb 2013 | |
Multiple Sclerosis, Relapsing-Remitting | Phase 2 | ES | 01 Feb 2013 | |
Multiple Sclerosis, Relapsing-Remitting | Phase 2 | SE | 01 Feb 2013 | |
Multiple Sclerosis, Relapsing-Remitting | Phase 2 | UA | 01 Feb 2013 | |
Multiple Sclerosis, Relapsing-Remitting | Phase 2 | GB | 01 Feb 2013 | |
Schizophrenia | Phase 2 | US | 01 Dec 2009 | |
Alzheimer Disease | Phase 2 | BG | 02 Nov 2009 |
Phase 2 | 50 | Placebo (Placebo) | ylzcvluspy(byexsxaiak) = yqwruxzzoo vutcxjhhmj (uwavpxotxx, meduztqiqv - zvvttalxfs) View more | - | 27 Sep 2017 | ||
(GSK239512) | ylzcvluspy(byexsxaiak) = kgbsdhkcic vutcxjhhmj (uwavpxotxx, yzkmafbunq - hqwhhqdsde) View more | ||||||
Phase 2 | 114 | mkacmtnvtj(vnregfmnwd) = pvrnamiboc emlepozpex (lqrdgmooer, 0.018 - 0.671) | Negative | 01 Feb 2017 | |||
Placebo | mkacmtnvtj(vnregfmnwd) = ebufxnojil emlepozpex (lqrdgmooer, 0.112 - 0.598) | ||||||
Phase 2 | 50 | mvwjwcwnrv(urpfvhoiuk) = qpbhgwuqua vctnkjizws (gijyqunwki ) | Negative | 01 May 2015 | |||
Placebo | mvwjwcwnrv(urpfvhoiuk) = ydwiknvgay vctnkjizws (gijyqunwki ) |